Considering that the anti-IL-6R antibody (tocilizumab) is an effective treatment for cytokine release syndrome in CAR-T cell therapies 28,36, researchers might want to consider drugs with a similar mechanism of action in COVID-19 treatment. Here, IL6R is linked to COVID-19.